Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
aTyr PharmaATYR +0.52%20 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates ATYR with a GF Score™ of 20/100 and a GF Value™ of $0.52 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, aTyr Pharma ranks worse than 118905.95% on this metric.
The historical rank and industry rank for aTyr Pharma's Days Sales Outstanding or its related term are showing as below:
ATYR's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.98 * Ranked among companies with meaningful Days Sales Outstanding only.
aTyr Pharma's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
aTyr Pharma (NAS:ATYR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
aTyr Pharma Days Sales Outstanding Related Terms
aTyr Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATYR vs TIL, AURX, ELOX: Days Sales Outstanding Comparison
For the Biotechnology subindustry, aTyr Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #999999 out of 841 companies in the Biotechnology industry.
Is aTyr Pharma's Days Sales Outstanding too high?
aTyr Pharma's current Days Sales Outstanding is 0.00. Based on the distribution chart, aTyr Pharma ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 20/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Days Sales Outstanding compare to TIL and AURX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #999999 out of 841 companies for Days Sales Outstanding. This places aTyr Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.38 — trading 26.1% below its estimated fair value. The current Days Sales Outstanding is 0.00. aTyr Pharma's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be undervalued.
The current stock price of $0.38 is trading 26.1% below its estimated GF Value™ of $0.52.
GuruFocus considers aTyr Pharma to be Modestly Undervalued.
Key valuation signals for ATYR:
Days Sales Outstanding: 0.00
GF Value™: $0.52 vs. price of $0.38 (26.1% below fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
20GF Score
Get the complete analysis for ATYR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
